Mayo Clinic, Rochester, Minnesota.
Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.
Clin Cancer Res. 2019 Jan 1;25(1):125-133. doi: 10.1158/1078-0432.CCR-18-1984. Epub 2018 Oct 9.
Colorectal cancers with deficient DNA mismatch repair (dMMR) are presumed to uniformly have dense lymphocytic infiltration that underlies their favorable prognosis and is critical to their responsiveness to immunotherapy, as compared with MMR-proficient (pMMR) tumors. We examined T-cell densities and their potential heterogeneity in a large cohort of dMMR tumors.
CD3 and CD8 T-cell densities were quantified at the invasive margin (IM) and tumor core (CT) in 561 stage III colon cancers (dMMR, = 278; pMMR, = 283) from a phase III adjuvant trial (N0147). Their association with overall survival (OS) was determined using multivariable Cox analysis.
Although CD3 and CD8 T-cell densities in the tumor microenvironment were higher in dMMR versus pMMR tumors overall, intertumoral heterogeneity in densities between tumors was significantly higher by 30% to 88% among dMMR versus pMMR cancers ( < 0.0001 for all four T-cell subtypes [CD3IM, CD3CT, CD8IM, CD8CT]). A substantial proportion of dMMR tumors (26% to 35% depending on the T-cell subtype) exhibited T-cell densities as low as that in the bottom half of pMMR tumors. All four T-cell subtypes were prognostic in dMMR with CD3IM being the most strongly prognostic. Low (vs. high) CD3IM was independently associated with poorer OS among dMMR (HR, 4.76; 95% confidence interval, 1.43-15.87; = 0.0019) and pMMR tumors ( = 0.0103).
Tumor-infiltrating T-cell densities exhibited greater intertumoral heterogeneity among dMMR than pMMR colon cancers, with CD3IM providing robust stratification of both dMMR and pMMR tumors for prognosis. Potentially, lower T-cell densities among dMMR tumors may contribute to immunotherapy resistance.
与错配修复(MMR)功能完整(pMMR)的肿瘤相比,DNA 错配修复缺陷(dMMR)的结直肠癌被认为普遍存在密集的淋巴细胞浸润,这是其预后良好的基础,也是对免疫治疗有反应的关键。我们在一个大型 dMMR 肿瘤队列中检查了 T 细胞密度及其潜在的异质性。
在一项 III 期辅助试验(N0147)中,对 561 例 III 期结肠癌患者的肿瘤边缘(IM)和肿瘤核心(CT)处的 CD3 和 CD8 T 细胞密度进行了定量(dMMR,n=278;pMMR,n=283)。使用多变量 Cox 分析确定其与总生存期(OS)的关系。
尽管 dMMR 肿瘤的肿瘤微环境中 CD3 和 CD8 T 细胞密度总体上高于 pMMR 肿瘤,但 dMMR 肿瘤之间的密度存在显著的肿瘤间异质性,dMMR 肿瘤比 pMMR 肿瘤高 30%至 88%(所有四种 T 细胞亚群[CD3IM、CD3CT、CD8IM、CD8CT]均 < 0.0001)。相当一部分 dMMR 肿瘤(取决于 T 细胞亚群,比例为 26%至 35%)的 T 细胞密度低至 pMMR 肿瘤的下半部分。在 dMMR 中,所有四种 T 细胞亚群均具有预后意义,其中 CD3IM 的预后意义最强。在 dMMR 中,低(高)CD3IM 与较差的 OS 独立相关(HR,4.76;95%置信区间,1.43-15.87; = 0.0019)和 pMMR 肿瘤( = 0.0103)。
与 pMMR 结肠癌相比,dMMR 结肠癌细胞浸润的 T 细胞密度存在更大的肿瘤间异质性,CD3IM 为 dMMR 和 pMMR 肿瘤的预后提供了强有力的分层。可能的原因是 dMMR 肿瘤中 T 细胞密度较低可能导致免疫治疗耐药。